Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a double-blind Phase III trial in 551 patients, 400 mg/day of Vimpat met the primary endpoint of a
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury